<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03799705</url>
  </required_header>
  <id_info>
    <org_study_id>18-001135</org_study_id>
    <nct_id>NCT03799705</nct_id>
  </id_info>
  <brief_title>Genetic Variants in Nicotinamide Adenine Dinucleotide (NAD) Synthesis Pathway</brief_title>
  <official_title>Identifying Genetic Variants in Nicotinamide Adenine Dinucleotide (NAD) Synthesis Pathway in Patients With Congenital Malformations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are trying to identify versions of genes as well as factors in subjects blood
      associated with certain types of congenital malformations(CMs). This study will help the
      researchers to better understand family traits that contribute to CMs.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genetic variants</measure>
    <time_frame>2 years</time_frame>
    <description>Identification of genetic variants which may be associated with VACTERL association or other congenital malformations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Targeted metabolomics</measure>
    <time_frame>2 years</time_frame>
    <description>Identification of changes in metabolic pathways which may provide functional insight into the presence of genetic variants in patients with VACTERL association</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">840</enrollment>
  <condition>Vacterl Association</condition>
  <condition>Congenital Malformation</condition>
  <arm_group>
    <arm_group_label>History of VACTERL or congenital malformations</arm_group_label>
    <description>1) Adults with VACTERL association; 2) adults with a history of congenital malformations resembling VACTERL association; 3) gravid and non-gravid women with a history of recurrent miscarriage, their surviving offspring, and the biological father of offspring; 4) newly diagnosed VACTERL patients identified by healthcare providers.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA and metabolites will be extracted from blood and urine for genetic variant and targeted
      metabolomics analyses.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A US population consisting of adults with VACTERL, adults and offspring with a family
        history of VACTERL, and women with a history of miscarriage and/or congenital
        malformations.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults with confirmed or putative diagnosis of VACTERL association;

          2. Families (mother, father, biological offspring) with a history of VACTERL-associated
             malformations

          3. Gravid or non-gravid women with a history of miscarriage and/or offspring with
             non-VACTERL-associated malformations

          4. Willingness to abstain from red meat, meat products, chicken, peanuts, or brewer's
             yeast (including beer) at least 24 hours prior to blood and urine collection

        Exclusion Criteria:

        1) Parents of non-biological children 3) Children with congenital malformations associated
        with an identifiable environmental or lifestyle exposure 4) Children with congenital
        malformations associated with confirmed chromosomal disorders 5) Failure to abstain from
        red meat, meat products, chicken, peanuts, or brewer's yeast (including beer) at least 24
        hours prior to blood and urine collection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Chini, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather LaBrec, BA</last_name>
    <phone>507-293-3446</phone>
    <email>LaBrec.Heather@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kelly A Hogan, Ph.D.</last_name>
    <phone>507-284-0746</phone>
    <email>hogan.kelly@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather LaBrec, BA</last_name>
      <phone>507-293-3446</phone>
      <email>LaBrec.Heather@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kelly A Hogan, Ph.D.</last_name>
      <phone>507-284-0746</phone>
      <email>hogan.kelly@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eduardo Chini, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>January 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2019</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Eduardo N. Chini</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

